Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy

Published:2019-03-12 Issue:13 Volume:11 Page:12342-12356
ISSN:1944-8244
Container-title:ACS Applied Materials & Interfaces
language:en
Short-container-title:ACS Appl. Mater. Interfaces

Author:

DuRoss Allison N.¹,Neufeld Megan J.¹,Landry Madeleine R.¹,Rosch Justin G.¹,Eaton Colin T.¹,Sahay Gaurav¹²^ORCID,Thomas Charles R.³,Sun Conroy¹³^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States

2. Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, Oregon 97201, United States

3. Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon 97239, United States

Funder

National Institute of Biomedical Imaging and Bioengineering

National Institute of General Medical Sciences

Oregon State University College of Pharmacy

Publisher

American Chemical Society (ACS)

Subject

General Materials Science

Link

https://pubs.acs.org/doi/pdf/10.1021/acsami.9b02408

Reference68 articles.

1. Cancer drug resistance: an evolving paradigm

2. Tumour heterogeneity and resistance to cancer therapies

3. The challenges of tumor genetic diversity

4. Evolutionary dynamics of cancer in response to targeted combination therapy

5. Combination therapy in combating cancer

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition;Radiotherapy and Oncology;2024-11

2. Application of nanostructure-loaded hydrogels for cancer treatment and tissue regeneration;Applied Materials Today;2024-04

3. Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy;Current Medicinal Chemistry;2024-02

4. Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review);International Journal of Oncology;2023-01-04

5. Targeting Breast Cancer Signaling via Phytomedicine and Nanomedicine;Pharmacology;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3